Oncology
Study maps self-reinforcing SRSF1–AURKA–MYC circuit in pancreatic cancer cells
Reported by AI Image generated by AI Fact checked
Researchers at Cold Spring Harbor Laboratory report they have identified a three-part molecular circuit involving SRSF1, Aurora kinase A (AURKA) and MYC that helps drive aggressive pancreatic ductal adenocarcinoma. In laboratory models, a splice-switching antisense oligonucleotide designed to alter AURKA splicing disrupted the circuit, reducing tumor-cell viability and triggering programmed cell death.
An alliance between Clínica Medilaser and the Instituto Médico Oncológico has consolidated an integrated program to treat central nervous system tumors in southern Colombia. The service, led by neurosurgeon Silvia Quintero, serves patients from several regions from its Neiva site.
Reported by AI
One month after the nationwide oncology sanitary alert took effect, Health Minister May Chomali led the signing of a decree transferring $154 billion from the Ministry of Hacienda to the Ministry of Health (Minsal). The funds will exclusively support the Oncology Alert Plan, enhancing public health services' capacity to resolve oncology waiting lists affecting thousands of patients.
Servier Egypt has launched Tibsovo (ivosidenib), the first targeted therapy available in the country for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and intrahepatic cholangiocarcinoma. The treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data. It is approved as a first-line treatment for AML and a second-line option for intrahepatic cholangiocarcinoma.
Reported by AI
Oncologist Paulo Hoff warned that excessive sun exposure is the most common cause of cancer, particularly non-melanoma skin cancer. In a course on CasaFolha, he emphasizes the importance of prevention and early diagnosis to boost cure rates. Hoff recommends avoiding the sun between 10am and 2pm and using sunscreen.
A combination of enzalutamide and hormone therapy has reduced the risk of death by more than 40% in men with recurring prostate cancer, according to a major clinical trial. The study, involving over 1,000 patients worldwide, was led by researchers at Cedars-Sinai and presented at a medical congress in Berlin. Experts describe the findings as a game changer for treating aggressive cases.
Reported by AI
Researchers at Spain's National Cancer Research Centre (CNIO) have developed a comprehensive catalog of mutational 'scars' in DNA caused by cancer. This breakthrough, published in Nature, could help bypass resistances to treatments like PARP inhibitors. The study analyzes thousands of tumor samples to identify key genetic patterns.
Sonora activates cancer-fighting linear accelerator and announces four hospital projects
March 10, 2026 18:13Roche shares decline after giredestrant trial fails endpoint
February 19, 2026 03:55Stf approves agreement for funding oncology treatments in Sus
February 18, 2026 04:47Egypt and Canada deepen healthcare cooperation focusing on digital health and oncology
February 13, 2026 17:37Cuba battles cancer amid shortages
November 20, 2025 14:53Weill Cornell team identifies CD47–TSP-1 signal behind T cell exhaustion; blocking it revives anti-tumor immunity in mice
November 02, 2025 03:05Clínica Medilaser leads blood cancer diagnosis and treatment
October 30, 2025 14:26Eastern Cape chemotherapy shortages risk pediatric patients
October 22, 2025 07:57Drug combination slows progression of aggressive prostate cancer
October 20, 2025 00:43Study confirms rise in cancer cases among adults under 50